TDMS Study 96003-03 Pathology Tables
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
FINAL#1/MICE
Facility: BIORELIANCE
Chemical CAS #: 106-95-6
Lock Date: 10/18/00
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include 008 VEHICLE CONTROL
Include 009 0.5 MG/KG
Include 010 1 MG/KG
Include 011 2 MG/KG
Include 012 4 MG/KG
Include 013 8 MG/KG
Include 001 VEHICLE CONTROL
Include 002 0.5 MG/KG
Include 003 1 MG/KG
Include 004 2 MG/KG
Include 005 4 MG/KG
Include 006 8 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Dosing Accident 2
Moribund Sacrifice 2 3 4 6 1 3
Natural Death 2 2 3 1 3
Survivors
Terminal Sacrifice 9 10 8 8 11 12
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (2)
Muscularis, Epithelium, Necrosis, Diffuse 1 (50%)
Muscularis, Periesophageal Tissue,
Inflammation, Chronic Active, Focal 1 (50%)
Periesophageal Tissue, Foreign Body, Focal 1 (50%)
Intestine Small, Duodenum (13) (14) (11) (12) (13) (15)
Serosa, Inflammation, Acute, Focal 1 (8%)
Liver (15) (15) (15) (15) (14) (15)
Hematopoietic Cell Proliferation 1 (7%) 1 (7%) 1 (7%)
Infiltration Cellular, Diffuse,
Polymorphonuclear 1 (7%) 1 (7%)
Inflammation, Acute, Focal 1 (7%) 1 (7%)
Inflammation, Chronic Active, Diffuse 1 (7%)
Necrosis, Chronic Active, Focal 1 (7%)
Necrosis, Focal 2 (13%) 2 (13%) 3 (20%) 2 (13%) 1 (7%) 2 (13%)
Centrilobular, Vacuolization Cytoplasmic 1 (7%)
Hepatocyte, Degeneration, Focal 1 (7%)
Hepatocyte, Necrosis, Focal 1 (7%) 1 (7%) 3 (20%) 5 (33%) 3 (21%) 4 (27%)
Hepatocyte, Vacuolization Cytoplasmic,
Diffuse 4 (27%) 5 (33%) 3 (20%) 4 (29%) 3 (20%)
Hepatocyte, Vacuolization Cytoplasmic, Focal 2 (13%) 2 (13%) 1 (7%) 4 (27%) 2 (14%) 3 (20%)
Hepatocyte, Periportal, Vacuolization
Cytoplasmic 1 (7%) 2 (13%)
Hepatocyte, Centrilobular, Vacuolization
Cytoplasmic 1 (7%)
Serosa, Inflammation, Acute, Focal 1 (7%)
Pancreas (1) (1) (1) (3)
Inflammation, Acute, Diffuse 1 (33%)
Necrosis, Focal 1 (100%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Acinus, Atrophy, Diffuse 1 (100%)
Stomach, Forestomach (14) (15) (12) (13) (14) (15)
Muscularis, Serosa, Inflammation, Acute,
Focal 1 (7%)
Stomach, Glandular (13) (14) (11) (13) (13) (15)
Serosa, Inflammation, Acute, Focal 1 (8%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (1)
Aorta, Inflammation, Chronic Active, Focal 1 (100%)
Heart (1) (1)
Atrium, Thrombosis, Focal 1 (100%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (13) (14) (12) (13) (12) (15)
Atrophy 4 (31%) 6 (43%) 9 (75%) 3 (23%) 11 (92%) 4 (27%)
Mineralization, Focal 1 (7%)
Subcapsular, Hyperplasia, Focal 2 (15%) 4 (29%) 3 (25%) 9 (69%) 5 (42%) 6 (40%)
Zona Reticularis, Hyperplasia, Diffuse 1 (8%)
Zona Reticularis, Infiltration Cellular,
Focal, Lymphocyte 1 (8%)
Zona Reticularis, Vacuolization Cytoplasmic,
Diffuse 6 (46%) 8 (57%) 6 (50%) 10 (77%) 9 (75%) 12 (80%)
Zona Reticularis, Vacuolization Cytoplasmic,
Focal 6 (46%) 4 (29%) 5 (42%) 2 (15%) 1 (8%) 3 (20%)
Thyroid Gland (13) (13) (12) (14) (12) (14)
Ectopic Thymus 1 (8%) 1 (8%)
Follicle, Cyst, Focal 1 (8%) 1 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (13) (15) (14) (14) (13) (15)
Angiectasis, Focal 1 (7%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Atrophy 2 (13%) 2 (14%) 1 (8%)
Cyst 1 (7%) 1 (8%)
Cyst, Focal 1 (7%)
Degeneration 1 (8%) 2 (14%) 1 (7%) 1 (8%) 1 (7%)
Inflammation, Acute, Diffuse 1 (8%)
Inflammation, Chronic Active, Diffuse 1 (8%)
Inflammation, Diffuse 1 (7%)
Bilateral, Inflammation, Chronic Active,
Diffuse 1 (8%)
Bilateral, Periovarian Tissue, Cyst 1 (8%)
Corpus Luteum, Inflammation, Chronic Active,
Focal 1 (7%)
Periovarian Tissue, Inflammation, Acute,
Focal 1 (7%)
Periovarian Tissue, Inflammation, Chronic
Active, Diffuse 1 (8%)
Periovarian Tissue, Inflammation, Chronic
Active, Focal 1 (7%) 1 (7%)
Periovarian Tissue, Rete Ovarii,
Inflammation, Acute, Focal 1 (7%) 1 (8%)
Uterus (13) (15) (13) (14) (12) (15)
Atrophy 1 (8%)
Hydrometra 1 (7%) 2 (14%)
Inflammation, Acute, Diffuse 1 (7%)
Inflammation, Acute, Focal 1 (8%)
Inflammation, Chronic Active, Diffuse 1 (8%)
Endometrium, Hyperplasia, Cystic 11 (85%) 10 (67%) 8 (62%) 4 (29%) 10 (83%) 13 (87%)
Endometrium, Inflammation, Acute, Focal 1 (8%)
Serosa, Inflammation, Acute, Focal 1 (8%)
Vagina (1)
Inflammation, Chronic Active, Diffuse 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (1)
Iliac, Hyperplasia 1 (100%)
Renal, Hyperplasia 1 (100%)
Lymph Node, Mandibular (14) (15) (12) (14) (12) (15)
Hyperplasia 2 (14%) 1 (7%) 2 (17%) 2 (13%)
Inflammation, Acute, Focal 1 (8%)
Necrosis, Focal 1 (7%)
Lymph Node, Mesenteric (13) (14) (12) (15) (12) (15)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hyperplasia 1 (8%)
Lymph Node, Mediastinal (14) (15) (14) (14) (12) (14)
Atrophy 1 (7%)
Hyperplasia 1 (7%) 1 (8%)
Inflammation, Diffuse 1 (7%)
Spleen (15) (14) (15) (15) (13) (15)
Hematopoietic Cell Proliferation 13 (87%) 11 (79%) 15 (100%) 13 (87%) 12 (92%) 14 (93%)
Pigmentation 10 (67%) 11 (79%) 10 (67%) 14 (93%) 11 (85%) 14 (93%)
Capsule, Inflammation, Acute, Focal 2 (15%)
Lymphoid Follicle, Depletion Cellular 1 (7%) 1 (7%) 1 (7%)
Thymus (13) (13) (12) (13) (11) (15)
Atrophy, Diffuse 5 (38%) 3 (23%) 2 (15%) 1 (7%)
Atrophy, Focal 2 (15%) 1 (8%) 3 (23%) 2 (18%) 6 (40%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (1)
Dilatation, Focal 1 (100%)
Skin (15) (15) (15) (15) (14) (15)
Dermis, Fibrosis, Focal 1 (7%)
Dermis, Subcutaneous Tissue, Inflammation,
Chronic Active, Diffuse 1 (7%)
Epidermis, Hyperplasia, Focal 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (14) (15) (15) (15) (14) (15)
Alveolus, Hemorrhage, Focal 1 (7%) 1 (7%)
Alveolus, Hyperplasia, Focal, Histiocytic 1 (7%)
Alveolus, Inflammation, Chronic, Focal 1 (7%)
Arteriole, Necrosis, Focal 1 (7%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Mediastinum, Inflammation, Acute, Focal 1 (7%) 1 (7%)
Perivascular, Infiltration Cellular,
Lymphocyte 1 (7%) 1 (7%) 1 (7%)
Serosa, Mediastinum, Inflammation, Chronic
Active, Focal 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (14) (14) (15) (13) (15)
Infiltration Cellular, Focal, Lymphocyte 1 (7%)
Inflammation, Chronic Active, Focal 1 (7%) 1 (8%)
Necrosis, Focal 1 (7%)
Bilateral, Inflammation, Acute, Focal 1 (7%) 1 (7%)
Bilateral, Nephropathy, Diffuse 1 (7%)
Capsule, Inflammation, Acute, Focal 1 (7%)
Cortex, Inflammation, Acute, Focal 1 (7%)
Cortex, Pelvis, Inflammation, Chronic Active,
Focal 1 (7%)
Papilla, Inflammation, Acute, Focal 1 (7%)
Renal Tubule, Degeneration, Focal 1 (7%)
Renal Tubule, Dilatation, Diffuse 1 (7%) 1 (7%) 1 (7%)
Renal Tubule, Dilatation, Focal 2 (13%) 1 (8%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Moribund Sacrifice 2 2 3 2 4 1
Natural Death 1 3 3 4 2
Dosing Accident 1 1 1 1
Survivors
Terminal Sacrifice 12 9 9 12 6 11
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (1) (1) (1) (1)
Muscularis, Periesophageal Tissue,
Inflammation, Chronic Active, Diffuse 1 (100%)
Periesophageal Tissue, Inflammation, Chronic
Active, Diffuse 1 (100%) 1 (100%)
Periesophageal Tissue, Inflammation, Chronic
Active, Focal 1 (100%)
Liver (14) (15) (14) (15) (14) (15)
Necrosis, Focal 1 (7%) 1 (7%)
Hepatocyte, Necrosis, Focal 2 (14%) 3 (20%) 5 (36%) 2 (14%)
Hepatocyte, Vacuolization Cytoplasmic,
Diffuse 1 (7%)
Hepatocyte, Vacuolization Cytoplasmic, Focal 1 (7%) 1 (7%) 2 (13%)
Hepatocyte, Centrilobular, Hypertrophy 1 (7%)
Hepatocyte, Centrilobular, Vacuolization
Cytoplasmic 2 (14%) 2 (14%) 1 (7%)
Serosa, Inflammation, Chronic Active, Focal 1 (7%)
Sinusoid, Inflammation, Focal 1 (7%)
Mesentery (1) (1) (2)
Fat, Necrosis, Focal 1 (100%) 1 (100%) 2 (100%)
Pancreas (1)
Acinus, Atrophy, Diffuse 1 (100%)
Salivary Glands (1) (1) (1)
Necrosis, Focal 1 (100%)
Tooth (5) (5) (4) (3) (6) (4)
Peridontal Tissue, Inflammation, Chronic
Active, Focal 1 (25%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (15) (14) (14) (14) (12) (14)
Atrophy 15 (100%) 13 (93%) 14 (100%) 14 (100%) 10 (83%) 12 (86%)
Degeneration, Focal 1 (7%)
Hypertrophy, Focal 13 (87%) 10 (71%) 9 (64%) 11 (79%) 10 (83%) 11 (79%)
Subcapsular, Hyperplasia, Focal 1 (7%)
Zona Reticularis, Vacuolization Cytoplasmic,
Focal 1 (7%) 1 (7%) 1 (8%) 1 (7%)
Thyroid Gland (15) (13) (14) (15) (9) (14)
Inflammation, Chronic Active, Focal 1 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Fat, Necrosis, Focal 1 (100%)
Mediastinum, Inflammation, Chronic Active,
Focal 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Preputial Gland (1) (2) (2) (1) (4) (2)
Ectasia 1 (100%) 1 (50%) 2 (100%) 1 (100%) 4 (100%) 2 (100%)
Inflammation, Chronic Active, Focal 1 (50%)
Seminal Vesicle (1) (1)
Dilatation 1 (100%)
Bilateral, Dilatation 1 (100%)
Testes (15) (15) (15) (15) (14) (14)
Germinal Epithelium, Degeneration, Diffuse 1 (7%)
Germinal Epithelium, Degeneration, Focal 1 (7%) 5 (33%) 1 (7%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node, Mandibular (15) (13) (14) (15) (13) (15)
Hyperplasia 1 (7%) 1 (8%) 2 (14%) 3 (23%) 1 (7%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hyperplasia, Histiocytic 1 (8%)
Lymph Node, Mesenteric (14) (14) (14) (15) (12) (14)
Hyperplasia 1 (7%)
Inflammation, Chronic Active, Focal 1 (7%)
Lymph Node, Mediastinal (14) (13) (14) (15) (10) (14)
Hyperplasia 1 (8%) 1 (7%)
Spleen (15) (14) (14) (15) (14) (15)
Congestion 1 (7%) 1 (7%)
Hematopoietic Cell Proliferation 14 (93%) 14 (100%) 13 (93%) 15 (100%) 12 (86%) 13 (87%)
Inflammation, Chronic Active, Focal 1 (7%)
Pigmentation 8 (53%) 10 (71%) 9 (64%) 12 (80%) 6 (43%) 11 (73%)
Lymphoid Follicle, Depletion Cellular 1 (7%) 1 (7%) 1 (7%) 1 (7%)
Thymus (15) (13) (12) (15) (10) (13)
Atrophy, Diffuse 3 (20%) 3 (23%) 2 (17%) 2 (13%) 3 (30%) 1 (8%)
Atrophy, Focal 1 (7%) 2 (15%) 1 (8%) 4 (27%) 1 (10%) 1 (8%)
Hyperplasia 2 (17%)
Hyperplasia, Focal 1 (10%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (14) (15)
Hyperkeratosis, Focal 1 (7%)
Dermis, Inflammation, Chronic Active, Focal 1 (7%)
Epidermis, Hyperplasia, Focal 1 (7%) 2 (13%)
Subcutaneous Tissue, Inflammation, Chronic
Active, Focal 1 (7%) 1 (7%)
Subcutaneous Tissue, Necrosis, Focal 1 (7%) 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (14) (15) (14) (15)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 96003-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: 39 WEEKS ALLYL BROMIDE Date: 03/30/01
Route: GAVAGE Time: 09:19:05
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE VEHICLE 0.5 1 MG/KG 2 MG/KG 4 MG/KG 8 MG/KG
CONTROL MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Inflammation, Chronic Active, Focal 1 (7%)
Alveolar Epithelium, Hyperplasia, Focal 1 (7%)
Alveolus, Hemorrhage, Focal 1 (7%) 1 (7%) 1 (7%)
Arteriole, Artery, Inflammation, Chronic
Active, Focal 2 (14%)
Arteriole, Capillary, Perivascular,
Inflammation, Acute 1 (7%)
Mediastinum, Inflammation, Chronic Active,
Diffuse 1 (7%)
Perivascular, Infiltration Cellular, Focal,
Lymphocyte 1 (7%) 1 (7%)
Perivascular, Infiltration Cellular,
Lymphocyte 1 (7%) 1 (7%) 1 (7%)
Serosa, Mediastinum, Inflammation, Chronic
Active, Diffuse 1 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1)
Retina, Atrophy 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (14) (14) (15) (14) (14)
Inflammation, Acute, Focal 1 (7%)
Inflammation, Chronic Active, Focal 1 (7%)
Bilateral, Cortex, Inflammation, Acute, Focal 1 (7%)
Capsule, Cortex, Inflammation, Chronic
Active, Focal 1 (7%)
Cortex, Inflammation, Acute, Focal 2 (14%)
Renal Tubule, Degeneration, Focal 2 (14%)
Renal Tubule, Dilatation, Diffuse 1 (7%) 1 (7%)
Renal Tubule, Dilatation, Focal 1 (7%) 1 (7%) 1 (7%) 1 (7%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------